Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of Coronavirus Disease-2019 on Hospital Care for Neonatal Opioid Withdrawal Syndrome

Kathryn Dee L. MacMillan, MD, MPH1,2, Tierney M. Morrison, MD3, Patrice Melvin, MPH4, Hafsatou Diop, MD, MPH5, Munish Gupta, MD, MMSc6, and Elisha M. Wachman, MD7

**Objective** To compare prenatal exposures, hospital care processes, and hospitalization outcomes for opioid-exposed newborns before and during the coronavirus disease 2019 (COVID-19) pandemic.

**Study design** In this multicenter retrospective analysis, data were collected from 19 Massachusetts hospitals, including 5 academic and 14 community hospitals. The pre-COVID-19 cohort was defined as births occurring during March 1, 2019-February 28, 2020, and the COVID-19 cohort was defined as births occurring during March 1, 2020-December 31, 2020. Opioid-exposed newborns born at ≥35 weeks of gestation were included. Differences in prenatal substance exposures, hospital care processes, and neonatal opioid withdrawal syndrome (NOWS) outcomes, including pharmacologic treatment for NOWS (PharmTx), length of stay (LOS), and as-needed (prn) treatment failure rates, were evaluated.

**Results** There were 663 opioid-exposed newborns in the pre-COVID-19 group and 476 in the COVID-19 group. No between-group differences were seen in prenatal substance exposures or the need for PharmTx. Compared with the pre-COVID-19 group, in the COVID-19 group there was less rooming-in after maternal discharge (53.8% vs 63.0%; \( P = .001 \)) and less care in the pediatric unit setting (23.5% vs 25.3%; \( P = .001 \)), longer LOS (adjusted risk ratio, 1.04; 95% CI, 1.01-1.08), and a higher rate of breast milk receipt at discharge (aOR, 2.03; 95% CI, 1.22-3.39). Within the subset of academic centers, more infants failed prn treatment in the COVID-19 group (53.8% vs 26.5%, \( P = .02 \); aOR, 3.77; 95% CI, 0.98-14.5).

**Conclusions** Among the hospitals in our collaborative, hospital processes for NOWS, including care setting, rooming-in, and LOS were negatively impacted in the COVID-19 group, particularly in academic medical centers.

---

Neonatal opioid withdrawal syndrome (NOWS) refers to a pattern of withdrawal signs in newborns resulting from chronic utero opioid exposure and characterized by behavioral dysregulation of the central nervous, autonomic nervous, respiratory, and gastrointestinal systems. Rates have increased significantly in recent years with the overall incidence of NOWS estimated at 8 per 1000 hospital births in the US in 2014. Wide geographic variation also exists, with the Northeast having the highest regional rate, at 9.5 per 1000 births.

Supporting nonpharmacologic care is a priority in management of NOWS and should be considered the foundation of care for all opioid-exposed newborns. Numerous quality improvement reports and several small randomized control trials have shown that nonpharmacologic interventions, such as rooming-in with parents, increasing parental presence at the bedside, breast milk feeding, decreasing environmental stimulation, and a variety of soothing techniques, improve NOWS outcomes, such as the need for pharmacologic treatment for NOWS (PharmTx), hospital length of stay (LOS), and weight trajectory.

Early recommendations encouraged separating newborns from mothers with confirmed or suspected COVID-19 to reduce the risk of transmission and potential risks of transmission associated with breastfeeding. As the understanding of COVID-19 has developed, clinical guidelines also have evolved, with greater emphasis on keeping biological parents and babies together and supporting lactation.

---

**Note:** Portions of this data were previously presented as an abstract during the 2021 Pediatric Academic Society annual meeting, April 30 - May 4, 2021 (Virtual).

---

| Abbreviation | Description |
|--------------|-------------|
| COVID-19     | Coronavirus disease 2019 |
| ER           | Emergency room |
| ESC          | Eat, Sleep, Console |
| LOS          | Length of stay |
| NICU         | Neonatal intensive care unit |
| NOWS         | Neonatal opioid withdrawal syndrome |
| OUD          | Opioid use disorder |
| PharmTx      | Pharmacologic treatment for neonatal opioid withdrawal syndrome |
| PNQIN        | Perinatal-Neonatal Quality Improvement Network of Massachusetts |
| Prn          | As necessary |
policies aimed at infection control also may adversely affect nonpharmacologic care for opioid-exposed newborns, including visitor restrictions, loss of volunteer cuddler programs, staff redeployment, and conversion of pediatric units into COVID-19 units, decreasing the space and opportunity for parental rooming-in.13-15

At the same time, during the COVID-19 pandemic there have been increases in the reported rates of community substance use and overdose, reflecting increased social and economic stressors.16-18 Although telehealth and updated guidance from the Substance Abuse and Mental Health Services Administration have provided opportunities for access to medication-assisted therapy through take-home dosing, access to other services may have been limited, with a decrease in attendance to group therapy reported among pregnant women in treatment programs for opioid use disorder (OUD).19-21 Data from the Massachusetts Department of Public Health indicate that the rate of NOWS increased from 11.7 to 14 per 1000 live births between 2018 and 2020-2021.

The impact of increased psychosocial stressors on medication for OUD dosing and unprescribed substance use in pregnancy remains unclear. We sought to utilize an ongoing statewide collaborative seeking to improve the care of families affected by perinatal opioid use to examine the impact of the COVID-19 pandemic on NOWS inpatient care.

**Methods**

This study was conducted under the umbrella of the Massachusetts Perinatal-Neonatal Quality Improvement Network (PNQIN), a statewide quality collaborative that includes birthing hospitals, community organizations, and state agencies, such as the Department of Children and Families and the Department of Public Health.22 Since 2016, the PNQIN has been involved in leading a NOWS improvement initiative focused on improving NOWS hospitalization outcomes through the increase of nonpharmacologic care measures, such as breast milk receipt and rooming-in. The initiative has included voluntary in-kind participation by multidisciplinary teams from 37 hospitals across the state of Massachusetts.

Hospitals participating in the PNQIN including a mix of academic medical centers and community hospitals that care for infants with NOWS in a variety of care settings. The majority of pregnant people with OUD in the PNQIN are receiving medication for OUD with methadone, buprenorphine, buprenorphine-naloxone, or naltrexone at the time of delivery.23 There was no uniform monitoring or treatment protocol required for centers for NOWS management, although many centers adapted a family-centered care approach focused on the use of nonpharmacologic care methods with use of the Eat, Sleep, Console (ESC) NOWS care tool.24 Infants were treated with either morphine or methadone as first-line pharmacotherapy, with clonidine or phenobarbital used as second-line agents. Some centers used prn (“as needed”) dosing of opioids.25 All infants were monitored in the hospital for 24-48 hours after the last dose of morphine or methadone before discharge to home.

**Data Collection**

Hospitals participating in the PNQIN collaborative voluntarily enter patient-level data into a statewide deidentified REDCap database on a monthly basis. Data points collected include birthing parent demographics, birthing parent drug exposures according to chart review data, birth demographics, details of the NOWS care setting and protocol, NOWS PharmTx details, nonpharmacologic care measures (eg, breastfeeding, rooming-in, skin-to-skin), discharge destination, and readmissions and emergency room (ER) visits within 30 days of infant discharge. All data are hand-abstracted by the hospital teams. This statewide quality improvement project was deemed nonhuman subjects research by the Institutional Review Boards at the PNQIN leadership team hospitals. All participating centers completed data use agreements with the PNQIN to be able to submit these deidentified data to the secure statewide database.

Criteria for inclusion of hospitals in this analysis were complete data entry into REDCap during both the pre-COVID-19 and COVID-19 periods. The pre-COVID-19 period was defined as births occurring during March 1, 2019-February 28, 2020, and the COVID-19 period was defined as births occurring during March 1, 2020-December 31, 2020, based on when the first surge of COVID-19 in Massachusetts occurred in March 2020. Infants had to have a known opioid exposure in pregnancy, as determined by a chart review of maternal records and/or maternal and infant toxicology screening, were cared for with a site-specific NOWS protocol, and to be at ≥35 weeks of gestational age at delivery for inclusion. Exclusion criteria included the birthing parent on naltrexone for the treatment of OUD. Data were reviewed for completeness, and sites were contacted about missing data before the final analysis.

**Outcome Measures**

Our primary outcome measures were related to NOWS hospitalization outcomes, specifically receipt of any PharmTx for NOWS, infant hospital LOS in days, days of opioid treatment, prn opioid treatment failure rates (defined as the transition from prn to standing opioid dosing), and any breast milk receipt at the time of discharge. Secondary outcome measures included infant custody at discharge and infant ER or hospital readmissions within 30 days of discharge. We also examined hospital process variables, including breastfeeding eligibility and initiation rates, rooming-in, skin-to-skin receipt, and location of infant care.

**Data Analyses**

We compared birthing parent and infant characteristics in the pre-COVID-19 and COVID-19 cohorts. Birthing parental variables examined included race and ethnicity, type of in utero opioid exposure including medication for OUD, unprescribed substance exposures, psychiatric medications, and eligibility to provide breast milk according to hospital guidelines. Infant variables included sex, gestational age at delivery, birth weight, location of care, receipt of breast milk, and NOWS hospital outcome measures.
Impact of Coronavirus Disease-2019 on Hospital Care for Neonatal Opioid Withdrawal Syndrome

Univariate comparisons were made between the pre-COVID-19 and COVID-19 groups using the $\chi^2$ test or Fisher exact test for categorical variables and the $t$ test for continuous variables. The Wilcoxon–Mann–Whitney test was used for medians. A subgroup analysis for NOWS outcomes was conducted among the 5 academic medical centers to examine potential effects from institutional pressures faced by larger centers converting pediatric spaces to accommodate adult COVID-19 patients, in addition to general physical space restrictions and COVID-19 precautions. Process measures and outcome measures were examined by univariate comparisons. Multivariate models were then used to examine determinants of primary outcome measures using mixed-effects logistic regression, including random intercepts for control of clustering by delivery hospital. Variables significantly associated with primary NOWS outcomes ($P < .05$) in univariate analyses were included in the regression models. All analyses were performed using SAS version 9.4 (SAS Institute).

Results

Of the 37 centers in the PNQIN, 26 participated in REDCap data entry to some degree since the start of the database. Of those 26, 7 were excluded from this analysis due to lack of data entry during the COVID-19 time period. This included 3 major academic medical centers and 4 smaller community hospitals that historically had a low volume of NOWS cases. From the remaining 19 centers, there were 1139 parent–infant dyads in our cohort, including 663 in the pre-COVID-19 group and 476 in the COVID-19 group. Five academic medical centers and 14 community hospitals were included, with a mix of level I, II, and III nurseries. Demographic characteristics of our cohort are summarized in Table I. There were slight differences in age of the birthing parent, race, and ethnicity between the 2 cohorts. Prenatal substances exposures did not differ significantly between the 2 groups, with the exception of other opioid exposures in the month before delivery (Table I). Infant birth outcomes of gestational age and birth weight did not differ between the 2 time periods.

Process measures and comparison of NOWS treatment protocols in the pre-COVID-19 and COVID-19 groups are displayed in Table II. All results were adjusted for clustering by center. In the COVID-19 group, there were significant decreases in rooming-in after parental discharge (53.8% vs 63.0%; $P = .001$) and in pediatric unit care during that time period (23.5% vs 25.3%; $P = .001$) (Table II). No significant differences in skin-to-skin receipt and breastfeeding eligibility and initiation rates were seen. More infants in the COVID-19 group were assessed with the ESC assessment method (71.6% vs 67.0%; $P = .002$). Of the 398 infants who received PharmTx, 348 (87.4%) were treated with morphine and 44 (11.1%) were treated with methadone in accordance with hospital guidelines. In addition, 118 of the 398 treated infants (29.6%) received prn dosing. Phenobarbital ($n = 4$) and clonidine ($n = 1$) were used as second-line agents.

Primary NOWS outcome measures are shown in Table II. There were no differences between the pre-COVID-19 and COVID-19 groups in NOWS PharmTx, LOS, days of opioid treatment, prn dosing failure rates, or receipt of breast milk at discharge in bivariate analyses. There also were no differences in our secondary outcomes of hospital readmissions or ER visits within 30 days or in infant custody status at discharge.

The association of covariates with our primary NOWS outcomes of PharmTx, LOS, and breast milk receipt at discharge were then examined (data not shown). There were significant differences by center, region, and center level for all primary outcomes. In addition, maternal medication for OUD was associated with multiple outcomes; specifically, methadone treatment was associated with higher rates of PharmTx and longer LOS, and buprenorphine treatment and no medication for OUD were associated with less PharmTx and shorter LOS. The rate of breast milk receipt was higher in buprenorphine-treated pregnant women and lower in those not on medication for OUD. Care location was significantly associated with differences, with infants cared for in a neonatal intensive care unit (NICU)/special care nursery and those cared for at academic centers having higher rates of PharmTx and longer LOS. Male infants had worse NOWS outcomes for both PharmTx and LOS. Exposures to unprescribed drugs, nicotine, and psychiatric medications were associated with higher rates of PharmTx, longer LOS, and lower rates of breast milk receipt at discharge. Any breast milk receipt during hospitalization was associated with less PharmTx and shorter LOS.

Our final multivariate regression models for the primary outcome measures for the entire cohort, adjusting for type of center (academic vs nonacademic), type of medication for OUD, care within a NICU/special care nursery (yes/no), selective serotonin reuptake inhibitor exposure (yes/no), benzodiazepine exposure (yes/no), and receipt of any breast milk (yes/no), and taking hospital-level clustering into account, are shown in Table III. There was no difference in PharmTx between the pre-COVID-19 and COVID-19 groups. There were higher rates of breast milk receipt at discharge (aOR, 2.03; 95% CI, 1.22–3.39) and longer hospital LOS (adjusted risk ratio, 1.04; 95% CI, 1.01–1.08) in the COVID-19 group. The prn treatment failure rate did not differ significantly between the 2 groups.

A subgroup analysis of the 5 academic medical centers ($n = 479$ infants; 305 in the pre-COVID-19 group and 177 in the COVID-19 group) did not indicate any differences in NOWS outcomes (bivariate data not shown), with the exception of a higher prn treatment failure rate in the COVID-19 cohort (14 of 26 [53.8%] vs 22 of 73 [30.1%]; $P = .02$) within these centers. Final multivariate regression models for the academic center subgroup are shown in Table IV. There were no differences in PharmTx or LOS between the pre-COVID-19 and COVID-19 groups. There was a higher rate of breast milk receipt at discharge in the COVID-19 group, as seen in the larger cohort (aOR,
2.93; 95% CI, 1.28-6.73). In the COVID-19 group, the aOR for prn treatment failure rate was 3.77 (95% CI, 0.98-14.50), which was no longer statistically significant.

**Discussion**

This study demonstrates changes in hospital care processes for newborns with prenatal opioid exposure in the COVID-19 era. Most notably, there was a significant decrease in opioid-exposed newborns who roomed-in with their parent after hospital discharge. Rooming-in of the parent–infant dyad is an important nonpharmacologic intervention that facilitates parental presence at the bedside and has been associated with improved hospital outcomes for opioid-exposed newborns. This decrease in rooming-in following discharge may reflect a decreased availability of bedspaces in areas of the hospital where rooming-in was not possible as the hospital’s COVID-19 patient load increased. Alternatively, this may reflect the impact of more stringent visitor policies in place to limit COVID-19 spread. Previous studies have demonstrated a negative impact of visitor restrictions on parental presence in the NICU and other pediatric units, as well as on parent experience during their child’s hospitalization. In some cases, limits on the number of visitors may have decreased the ability of fathers and other family members or support persons to visit, impacting the feasibility of an extended maternal stay at bedside. In other cases, the change in maternal status from patient to visitor might have precluded the mother’s ability to stay overnight with limited visitation hours.

### Table I. Demographic characteristics

| Characteristics                | Overall (N = 1139) | Pre-COVID-19 group (N = 663) | COVID-19 group (N = 476) | P value |
|--------------------------------|--------------------|------------------------------|--------------------------|---------|
| Region, n (%)                  |                    |                              |                          |         |
| Western Massachusetts          | 242 (21.2)         | 164 (24.7)                   | 78 (16.4)                | .004    |
| Central Massachusetts          | 183 (16.1)         | 106 (16.0)                   | 77 (16.2)                |         |
| Northeast Massachusetts        | 162 (14.2)         | 97 (14.6)                    | 65 (13.7)                |         |
| Boston metropolitan areas      | 208 (18.3)         | 118 (17.8)                   | 90 (18.9)                |         |
| Southeast Massachusetts        | 344 (30.2)         | 178 (26.8)                   | 166 (34.9)               |         |
| NICU level, n (%)              |                    |                              |                          |         |
| Level I                        | 220 (19.3)         | 118 (17.8)                   | 102 (21.4)               | .13     |
| Level II/III                   | 919 (80.7)         | 545 (82.2)                   | 374 (78.6)               |         |
| Center type, n (%)             |                    |                              |                          | .003    |
| Academic center                | 482 (42.3)         | 305 (46.0)                   | 177 (37.2)               |         |
| Nonacademic center             | 657 (57.7)         | 358 (54.0)                   | 299 (62.8)               |         |
| Birthing parent age, y, mean (SD) | 31.2 (4.7)    | 30.9 (4.9)                    | 31.5 (4.4)               | .03     |
| Birthing parent race and ethnicity, n (%) | 102 (9.0)  | 71 (10.7)                     | 31 (6.5)                 | .01     |
| Hispanic                       | 38 (3.3)           | 24 (3.6)                     | 14 (2.9)                 |         |
| Non-Hispanic Black             | 931 (81.7)         | 542 (81.7)                   | 389 (81.7)               |         |
| Other                          | 34 (3.0)           | 14 (2.1)                     | 20 (4.2)                 |         |
| Unknown                        | 34 (3.0)           | 12 (1.8)                     | 22 (4.6)                 |         |
| Opioid exposure group, n (%)   |                    |                              |                          |         |
| Medication for OUD alone       | 679 (59.6)         | 390 (58.8)                   | 289 (60.7)               | .19     |
| Unprescribed opioids without medication for OUD | 124 (10.9)     | 65 (9.8)                     | 59 (12.4)                |         |
| Medication for OUD and unprescribed opioids | 295 (25.9)   | 182 (27.5)                   | 113 (23.7)               |         |
| Other opioids prescribed       | 41 (3.6)           | 26 (3.9)                     | 15 (3.2)                 |         |
| Medication for OUD, n (%)      |                    |                              |                          |         |
| Methadone                      | 449 (39.4)         | 280 (42.2)                   | 169 (35.5)               | .21     |
| Buprenorphine                  | 510 (44.8)         | 284 (42.8)                   | 226 (47.5)               |         |
| Methadone and buprenorphine    | 15 (1.3)           | 8 (1.2)                      | 7 (1.5)                  |         |
| Neither                        | 165 (14.5)         | 91 (13.6)                    | 74 (15.5)                |         |
| Unprescribed substances (opioids or cocaine), n (%) | 457 (40.1) | 268 (40.4)                   | 189 (39.7)               | .68     |
| Which unprescribed substance, n (%) | 333 (29.2) | 197 (29.7)                    | 136 (28.6)               | .46     |
| Cannabis                       | 105 (9.2)          | 57 (8.6)                     | 48 (10.1)                | .62     |
| Heroin (1 mo before delivery)  | 102 (9.0)          | 59 (8.9)                     | 43 (9.0)                 | .80     |
| Other opioids (1 mo before delivery) | 66 (5.8) | 47 (7.1)                      | 19 (4.0)                 | .02     |
| Cocaine                        | 221 (19.4)         | 124 (18.7)                   | 97 (20.4)                | .37     |
| Selective serotonin reuptake inhibitor, n (%) | 135 (11.9) | 77 (11.6)                      | 58 (12.2)                | .60     |
| Benzodiazepines, n (%)         | 183 (16.1)         | 109 (16.4)                   | 74 (15.5)                | .66     |
| Gabapentin, n (%)              | 115 (10.1)         | 69 (10.4)                    | 46 (9.7)                 | .72     |
| Nicotine smoking, n (%)        | 649 (57.0)         | 390 (58.8)                   | 259 (54.4)               | .07     |
| Eligible to provide breast milk, n (%) | 781 (68.7) | 445 (67.3)                    | 336 (70.6)               | .36     |
| Male infant, n (%)             | 591 (51.9)         | 333 (50.2)                   | 258 (54.2)               | .193    |
| Gestational age at delivery, wk, mean (SD) | 38.3 (1.5) | 38.2 (1.5)                     | 38.3 (1.6)               | .341    |
| Preterm <37 weeks of gestational age, n (%) | 166 (14.6) | 98 (14.8)                      | 68 (14.3)                | .705    |
| Birth weight, g, mean (SD)     | 3027.8 (521.3)     | 3022.02 (520.9)              | 3035.86 (522.3)          | .659    |

Significant P values are in bold type.
There was also a significant decrease in opioid-exposed newborns cared for in pediatric inpatient units. Presumably, this reflects in part the decreased availability of beds on noninpatient units as hospitals’ COVID-19 census increased. In several locations, adult patients with Covid-19 were cared for on units previously designated for pediatric care. This decrease in pediatric unit utilization likely contributed to the decrease in rooming-in after maternal discharge. Of note, a higher proportion of opioid-exposed newborns were cared for at nonacademic sites during the COVID-19 period, and many of these sites do not have inpatient pediatric units available.

Overall, NOWS hospitalization outcomes were stable from the pre-COVID-19 period to the COVID-19 period, with no significant changes in the overall rate of pharmacotherapy or any clinically significant differences in hospital LOS. A greater proportion of newborns in the COVID-19 period were managed using ESC assessment. This likely reflects a temporal trend as the selection of NOWS assessment model is made at the hospital level, with increased adoption of ESC over time. Management using ESC has been associated with a decreased need for PharmTx and decreased LOS, which might have been more subject to system-level pressures as many became dedicated centers for COVID-19 care, converting units to accommodate transfers. We hypothesize that the decreased success of limited prn doses may have been driven by changes in care settings, as well as other potential changes in provision of nonpharmacologic care.

There was a significant increase in the rate of breast milk receipt during the COVID-19 period. This finding was unexpected, given that previous studies reflected early concerns about potential COVID-19 transmission related to breast milk and demonstrated a decrease in hospital practices supporting breastfeeding. The reason for this association is uncertain. It is possible that with birthing parents anticipating more time at home owing to quarantine restrictions, increased availability of remote work for those working from home, and the promise of financial support for those not working, more mothers felt confident that they would be able to maintain a breastfeeding relationship after discharge. It is also possible that some parents may have hoped to provide immunologic protection for their newborn. Finally, there may have been another unidentified temporal trend toward greater breastfeeding education and support within this quality improvement network unrelated to the pandemic over this period.

### Table II. System process variables and NOWS outcomes

| Variables | Overall (N = 1139) | Pre-COVID-19 group (N = 663) | COVID-19 group (N = 476) | P value |
|-----------|------------------|-----------------------------|---------------------------|--------|
| Process measures and NOWS treatment protocol | | | | |
| Room-in before parental discharge, n (%) | 948 (83.5) | 552 (83.6) | 396 (83.2) | .54 |
| Rooming-in after parental discharge, n (%) | 962 (59.1) | 408 (63.0) | 254 (53.8) | .001 |
| Received skin to skin, n (%) | 930 (81.9) | 546 (82.6) | 384 (80.8) | .26 |
| Location of care, n (%) | | | | |
| NICU/SCN | 423 (37.1) | 253 (38.2) | 170 (35.7) | .71 |
| Nursery | 1020 (89.6) | 589 (57.8) | 431 (42.3) | .64 |
| Pediatric unit | 280 (24.6) | 168 (25.3) | 112 (23.5) | .001 |
| Parent eligible to provide breast milk, n (%) | 781 (68.7) | 445 (67.3) | 336 (70.6) | .36 |
| Received breast milk, n (%) | 613 (53.9) | 365 (55.1) | 248 (52.1) | .56 |
| NOWS assessment method, n (%) | | | | |
| Finnegan | 354 (31.1) | 219 (33.0) | 135 (28.4) | .002 |
| ESC | 785 (68.9) | 444 (67.0) | 341 (71.6) | |
| NOWS medications, n (%) | | | | |
| Morphine | 350 (87.5) | 208 (87.8) | 142 (87.1) | .65 |
| Methadone | 44 (11.0) | 25 (10.5) | 19 (11.7) | .13 |
| Clonidine | 1 (0.3) | 1 (0.4) | 0 (0.0) | .001 |
| Phenobarbital | 4 (1.0) | 3 (1.3) | 1 (0.6) | .001 |
| Feeding breast milk at discharge, n (%) | 528 (46.5) | 303 (46.0) | 225 (47.3) | .29 |
| PharmacTX, n (%) | 400 (35.5) | 237 (36.2) | 163 (34.5) | .80 |
| Prn opioid treatment of those with PharmacTX, n (%) | 119 (29.8) | 73 (30.8) | 46 (28.2) | .55 |
| Prn treatment failure rate, n (%) | 42 (35.3) | 22 (30.1) | 20 (43.5) | .14 |
| Opioid treatment days, mean (SD) | 15.5 (10.9) | 15.5 (10.6) | 15.5 (10.9) | .66 |
| Hospital LOS, d, mean (SD) | 12.3 (10.3) | 12.2 (9.9) | 12.5 (10.9) | .66 |
| Secondary outcome measures | | | | |
| Discharged in parental custody, n (%) | 856 (75.2) | 498 (75.1) | 358 (75.4) | .52 |
| ER visit within 30 d, n (%) | 38 (3.3) | 24 (3.6) | 14 (2.9) | .39 |
| Inpatient readmission within 30 d, n (%) | 18 (1.6) | 13 (2.0) | 5 (1.1) | .66 |

SCN, special care nursery.

P values account for hospital-level clustering using the Cochran–Mantel–Haenszel χ² test and mixed-effects regression analysis. Significant P values are in bold type.
| Factors                      | Breast milk at discharge | PharmTx | Hospital LOS | Failed prn treatment |
|-----------------------------|--------------------------|---------|--------------|----------------------|
|                             | % Breastfed | aOR, 95% CI | P value | % PharmTx | aOR, 95% CI | P value | Mean LOS | aRR, 95% CI | P value | % Failed prn | aOR, 95% CI | P value |
| Group                       |                          |         |              |          |              |         |          |              |         |              |              |        |
| Pre-COVID-19                | 46.0                     | Reference | .007        | 36.2     | Reference | .63 | 12.2     | Reference | .02 | 30.1         | Reference | .36 |
| COVID-19                    | 47.3                     | 2.03 (1.22-3.39) | .63 | 34.5     | 0.92 (0.65-1.30) | .63 | 12.5     | 1.04 (1.01-1.08) | .90 | 43.5         | 1.56 (0.60-4.09) | .15 |
| Center type                 |                          |         |              |          |              |         |          |              |         |              |              |        |
| Academic                    | 50.7                     | 1.24 (0.54-2.87) | .62 | 39.4     | 0.65 (0.23-1.86) | .42 | 14.0     | 1.02 (0.79-1.31) | .90 | 36.0         | 0.08 (0.00-2.57) | .15 |
| Nonacademic                 | 43.4                     | Reference | .11 | 32.6     | Reference | .36 | 11.1     | Reference | .34 |               |              |        |
| Medication for OUD          |                          |         |              |          |              |         |          |              |         |              |              |        |
| Methadone                   | 43.8                     | Reference | .86 | 44.3     | Reference | .002 | 14.6     | Reference | <.001 | 40.3         | Reference | .11 |
| Buprenorphine               | 55.1                     | 1.22 (0.73-2.03) | .25 | 25.8     | 0.51 (0.35-0.73) | .03 | 10.0     | 0.80 (0.77-0.83) | .38 | 23.8         | 0.31 (0.10-0.93) | .83 |
| None                        | 27.9                     | 1.01 (0.44-2.32) | .11 | 41.5     | 0.87 (0.53-1.44) | .11 | 13.3     | 0.89 (0.64-0.93) | .50 | 50.0         | 0.61 (0.16-4.08) | .67 |
| NICU/SCN                    |                          |         |              |          |              |         |          |              |         |              |              |        |
| Yes                         | 33.0                     | 0.57 (0.33-0.97) | .04 | 72.4     | 24.10 (16.19-35.93) | <.001 | 12.2     | 2.46 (2.37-2.56) | <.001 | 37.5         | 2.20 (0.74-6.58) | .16 |
| No                          | 54.5                     | Reference | .04 | 13.6     | Reference | .002 | 5.1      | Reference | .03 | 32.7         | Reference | .67 |
| SSRI                        |                          |         |              |          |              |         |          |              |         |              |              |        |
| Yes                         | 45.2                     | 1.51 (0.69-3.32) | .31 | 45.8     | 1.64 (0.97-2.75) | .06 | 9.5      | 1.05 (0.99-1.10) | .09 | 42.3         | 0.58 (0.27-2.84) | .83 |
| No                          | 46.7                     | Reference | .31 | 34.1     | Reference | .002 | 10.4     | Reference | .33 |               | Reference | .67 |
| Benzodiazepines             |                          |         |              |          |              |         |          |              |         |              |              |        |
| Yes                         | 30.1                     | 0.29 (0.16-0.52) | <.001 | 59.7     | 2.71 (1.72-4.26) | <.001 | 13.4     | 1.30 (1.25-1.35) | <.001 | 44.1         | 2.29 (0.76-6.88) | .14 |
| No                          | 49.7                     | Reference | .31 | 30.9     | Reference | .001 | 9.1      | Reference | .31 |               | Reference | .67 |
| Any breast milk             |                          |         |              |          |              |         |          |              |         |              |              |        |
| Yes                         | N/A                      | N/A     | N/A          | 24.6     | 0.40 (0.28-0.56) | <.001 | 8.9      | 0.79 (0.76-0.82) | <.001 | 26.0         | 0.80 (0.28-2.31) | .67 |
| No                          | N/A                      | N/A     | N/A          | 48.3     | Reference | .001 | 11.1     | Reference | .42 |               | Reference | .67 |

aRR, adjusted risk ratio; N/A, not applicable; SSRI, selective serotonin reuptake inhibitor.
Significant P-values are in bold type.
*Multivariable mixed-effects logistic regression model, taking into account hospital-level clustering.
†Multivariable mixed-effects Poisson regression model, taking into account hospital-level clustering.
‡Among pharmacologically treated infants on prn (n = 75).
Table IV. Multivariable regression of primary NOWS outcomes at academic centers

| Factors                        | Breast milk at discharge* | PharmTx*             | Hospital LOS†   | Failed prn treatment‡* | % Breastfed | aOR, 95% CI | P value | % PharmTx | aOR, 95% CI | P value | Mean LOS | aRR, 95% CI | P value | % Failed prn | aOR, 95% CI | P value |
|-------------------------------|---------------------------|----------------------|-----------------|-----------------------|-------------|--------------|---------|------------|--------------|---------|-----------|--------------|---------|-------------|--------------|---------|
| Group                         |                           |                      |                 |                       | 48.7        | Reference    | .01     | 39.6       | Reference    | .13     | 13.2      | Reference    | .48     | 26.5       | Reference    | .05     |
| Pre-COVID-19                  |                           |                      |                 |                       | Reference   | .01          |         | Reference  | .01          |         | Reference | .01          |         | Reference  | .01          |         |
| COVID-19                      | 54.2                      | 2.93 (1.28-6.73)     | 39.0            | 0.66 (0.39-1.12)      | 15.3        | 1.02 (0.97-1.07) | .48     | 53.9       | 3.77 (0.98-14.50) | .05     |
| Medication for OUD            |                           |                      |                 |                       | 49.0        | Reference    | .92     | 46.2       | Reference    | .10     | 16.1      | Reference    | <.001   | 47.7       | Reference    | .02     |
| Methadone                     |                           |                      |                 |                       | Reference   | .92          |         | Reference  | .92          |         | Reference | .92          |         | Reference  | .92          |         |
| Buprenorphine                 | 57.4                      | 0.82 (0.38-1.77)     | 29.8            | 0.52 (0.30-0.88)      | 11.5        | 0.78 (0.74-0.82) | .02     | 20.8       | 0.17 (0.04-0.72) | .02     |
| None                          | 32.8                      | 0.68 (0.21-2.24)     | 46.6            | 0.73 (0.34-1.57)      | 14.9        | 0.81 (0.75-0.88) | .02     | 14.3       | 0.05 (0.00-0.83) | .02     |
| NICU/SCN                      |                           |                      |                 |                       | 37.6        | 0.52 (0.25-1.09) | .08     | 68.9       | 16.49 (6.69-28.07) | <.001   | 21.2      | 2.59 (2.45-2.75) | <.001   |
| Yes                           | 37.6                      | 0.52 (0.25-1.09)     | 68.9            | 16.49 (6.69-28.07)    | <.001       | 21.2         | 2.59 (2.45-2.75) | <.001   | 36.7       | 2.64 (0.60-11.55) | .20     |
| No                            | 62.5                      | Reference            | 12.7            | Reference             | 7.4         | Reference    |         | 7.4        | Reference    |         | 34.6      | Reference    |         |
| SSRI                          |                           |                      |                 |                       | 47.3        | 1.50 (0.46-4.89) | .51     | 50.0       | 1.22 (0.54-2.75) | .63     | 15.3      | 0.99 (0.91-1.07) | .77     |
| Yes                           |                           |                      |                 |                       | Reference   | .51          |         | 50.0       | 1.22 (0.54-2.75) | .63     | 15.3      | 0.99 (0.91-1.07) | .77     |
| No                            | 51.2                      | Reference            | 38.0            | Reference             | 13.8        | Reference    |         | 13.8       | Reference    |         | Reference | Reference    |         |
| Benzodiazepines               |                           |                      |                 |                       | 30.7        | 0.17 (0.07-0.39) | <.001  | 63.4       | 3.49 (1.89-6.46) | <.001   | 20.1      | 1.31 (1.24-1.39) | <.001   |
| Yes                           |                           |                      |                 |                       | Reference   | <.001        |         | 63.4       | 3.49 (1.89-6.46) | <.001   | 20.1      | 1.31 (1.24-1.39) | <.001   |
| No                            | 56.1                      | Reference            | 33.0            | Reference             | 12.3        | Reference    |         | 12.3       | Reference    |         | 31.9      | Reference    |         |
| Any breast milk               |                           |                      |                 |                       | 27.1        | 0.35 (0.21-0.57) | <.001  | 10.6       | 0.74 (0.70-0.77) | <.001   | 24.2      | 0.51 (0.13-2.00) | .33     |
| Yes                           |                           |                      |                 |                       | 57.1        | Reference    |         | 10.6       | 0.74 (0.70-0.77) | <.001   | 45.2      | Reference    |         |
| No                            | 56.1                      | Reference            | 33.0            | Reference             | 12.3        | Reference    |         | 12.3       | Reference    |         | 31.9      | Reference    |         |

Significant P values are in bold type.

*Multivariable mixed-effects logistic regression model, taking into account hospital-level clustering.
†Multivariable mixed-effects Poisson regression model, taking into account hospital-level clustering.
‡Among pharmacologically treated infants on prn (n = 75).
Although previous studies have shown increases in community rates of opioid use and overdose, our findings did not demonstrate a significant increase in newborns exposed to nonprescribed opioids or other substances. Overall rates of birthing parents on medication for OUD were stable. Previous studies have documented increased availability of telehealth and take-home dosing. It is possible that improved maternal access to treatment of medication for OUD provided a balance to other social and financial pressures influencing unprescribed substance use during the pandemic. Alternatively, there is the potential that some cases of prenatal opioid exposure were missed in infants born to parents without a previously documented history of substance use disorder or treatment.

Strengths of this study include its coverage of multiple sites and care settings that are already routinely entering data on opioid-exposed newborns and therefore well-positioned to capture significant changes over time and its large number of parent–infant dyads. In addition, it included sites with different approaches to NOWS assessment and management. The baseline characteristics of birthing parents included in the pre-COVID-19 and COVID-19 periods were similar, including overall rates of medication for OUD and polysubstance exposures, which may influence neonatal outcomes. Of note, the percentage of infants exposed to medication for OUD was higher in our Massachusetts cohort compared with the general US population of pregnant individuals with OUD. Given the stable rate of medication for OUD over the pre-COVID-19 and COVID-19 periods and the identical NOWS treatment algorithm for all opioid-exposed infants regardless of type of opioid exposure, our results still would be generalizable to other settings.

This study has several limitations. Because this was not a controlled trial, there is a potential for other confounders or temporal trends impacting NOWS processes and outcomes in ways that we were unable to identify. It is possible that such data as maternal exposure to nicotine were underreported, given our reliance on chart abstraction owing to the limitations of our study design. Not all sites within the PNQIN network continued to enter data during the COVID-19 pandemic. Some enrolled sites had ceased regularly entering data before the pandemic; however, it is possible that sites more adversely affected by the pandemic had less staffing capacity to continue to enter data, or that sites that did continue to enter data had less infrastructure to support NOWS care in general. Of the 7 centers that stopped entering data during the pandemic, 3 were major academic medical centers in Boston significantly impacted by the COVID-19 patient burden. These centers historically have had low numbers of infants with NOWS, and data entry likely was not a high priority during the COVID-19 surge.

Additional limitations include the unclear proportion of newborns who were cared for in a level 1 infant-only nursery rather than a mother–baby room following maternal discharge versus being transferred to other units. It also is unclear whether newborns who otherwise might have been transferred to inpatient pediatric units were kept in mother–baby rooms longer or were transferred to level II/III nurseries. In addition, data on birthing parent COVID-19 status at or near delivery were not tracked as part of this study, and thus we were unable to draw any conclusions about how precautions to prevent transmission from birthing parent to baby may have impacted rooming-in, care site and other hospital processes, or NOWS outcomes for this subset of dyads.

Future directions include updated site practice surveys to better understand management of NOWS at each of the participating sites and site-identified facilitators and barriers to providing optimal care. In addition, parental questionnaires would help identify additional facilitators and barriers as perceived by the families. A better understanding of factors that promoted resiliency in this hospital network to pressures of the COVID-19 pandemic will be valuable for improving care as other areas of the country continue to experience surges in the COVID-19 pandemic, as well as preparing for possible future public health crises. It will be of interest to better understand facilitators and barriers to breastfeeding in this population and how these may have evolved with changes to community supports, interaction with the medical system through telehealth, and the potential impact of changes in remote versus onsite employment opportunities for parents who plan to return to work. The Massachusetts sites participating in the PNQIN have a history of quality improvement surrounding perinatal care of families impacted by OUD. In addition, even though Massachusetts experienced high rates of COVID-19 in the community and COVID-19–related hospitalizations earlier in the pandemic, later surges did not reach the same scale. It would be of interest to explore the impact of the COVID-19 pandemic on hospital care processes and outcomes for opioid-exposed newborns in other regions.

We thank the Massachusetts Perinatal Neonatal Quality Improvement Network’s Perinatal Opioid Project leadership team, particularly Mary Houghton and Allison Doyle, and all participating hospital teams who contributed data for this project.

Submitted for publication Dec 4, 2021; last revision received Jan 24, 2022; accepted Feb 1, 2022.

Reprint requests: Elisha Wachman, MD, Division of Neonatology, Department of Pediatrics, Boston Medical Center, 801 Albany Street, Floor 2, Room 2007, Boston, MA 02119. E-mail: Elisha.Wachman@bmc.org

References

1. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141–58.
2. Patrick SW, Barfield WD, Poindexter BB. Neonatal opioid withdrawal syndrome. Pediatrics 2020;146:e2020029074.
3. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650–5.
4. Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of neonatal abstinence syndrome—28 states, 1999–2013. MMWR Morb Mortal Wkly Rep 2016;65:799–802.
5. Villapiano NLG, Winkelman TNA, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013. JAMA Pediatr 2017;171:194–6.
6. Avram CM, Vich L, Dukhovny D, Caughhey TB. A cost-effectiveness analysis of rooming-in and breastfeeding in neonatal opioid withdrawal. Am J Perinatol 2020;37:1–7.
7. MacMillan KDL, Rendon CP, Verma K, Rübel N, Washner DB, Volpe Holmes A. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatr 2018;172:345–51.
8. Howard MB, Schiff DM, Penwill N, Si W, Rai A, Wolfgang T, et al. Impact of parental presence at infants’ bedside on neonatal abstinence syndrome. Hosp Pediatr 2017;7:63–9.
9. Pahl A, Young L, Iwashyna TJ, Costa DK. Visitor guidelines for opioid withdrawal in newborns. Cochrane Database Syst Rev 2020;12:CD013217.
10. Favara MT, Carola D, Jensen E, Cook A, Genen L, Dysart K, et al. Maternal breast milk feeding and length of treatment in infants with neonatal abstinence syndrome. J Perinatol 2019;39:876–82.
11. American Academy of Pediatrics. FAQs: Management of infants born to mothers with suspected or confirmed COVID-19. Updated May 5, 2021. Accessed August 18, 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers/
12. Flannery DD, Puopolo KM. Perinatal COVID-19: guideline development, implementation, and challenges. Curr Opin Pediatr 2021;33:188–94.
13. Vance AJ, Duy J, Laventhal N, Iwashyna TJ, Costa DK. Visitor guidelines in US children’s hospitals during COVID-19. Hosp Pediatr 2021;11:e83–9.
14. Kitano T, Piché-Renaud PP, Groves HE, Streitenberger L, Freeman R, Science M. Visitor restriction policy on pediatric wards during novel coronavirus (COVID-19) outbreak: a survey study across North America. J Pediatric Infect Dis Soc 2020;9:766–8.
15. Meier KA, Jerardi KE, Statlle AM, Shah SS. Pediatric hospital medicine management, staffing, and well-being in the face of COVID-19. J Hosp Med 2020;15:308–10.
16. Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med 2020;173:57–8.
17. Slavova S, Rock P, Bush HM, Queensberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend 2020;214:108176.
18. Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA 2020;324:1673–4.
19. Silva MJ, Kelly Z. The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment alternatives. Am J Manag Care 2020;26:e202–4.
20. Guille C, McCauley JL, Moreland A. Leveraging telehealth in the United States to increase access to opioid use disorder treatment in pregnancy and postpartum during the COVID-19 pandemic. Am J Psychiatry 2021;178:290–3.
21. McKiefer ME, Cleary EM, Schmauder T, Talley A, Hindy KA, Costantine MM, et al. Unintended consequences of the transition to telehealth for pregnancies complicated by opioid use disorder during the coronavirus disease 2019 pandemic. Am J Obstet Gynecol 2020;223:770–2.
22. The Perinatal-Neonatal Quality Improvement Network of Massachusetts. Perinatal opioid project (POP). Accessed August 18, 2021. https://www.pnqinma.org/perinatal-opioid-project
23. Singh R, Houghton M, Melvin P, Wachman EM, Diop H, Iverson R Jr, et al. Predictors of pharmacologic therapy for neonatal opioid withdrawal syndrome: a retrospective analysis of a statewide database. J Perinatol 2021;41:1381–8.
24. Wachman EM, Houghton M, Melvin P, Isley BC, Murzycki J, Singh R, et al. A quality improvement initiative to implement the eat, sleep, console neonatal opioid withdrawal syndrome care tool in Massachusetts’ PNQIN collaborative. J Perinatol 2020;40:1560–9.
25. Wachman EM, Minear S, Hirashima M, Hansbury A, Hutton E, Shrestha H, et al. Standard fixed-schedule methadone taper versus symptom-triggered methadone approach for treatment of neonatal opioid withdrawal syndrome. Hosp Pediatr 2019;9:576–84.
26. Bembich S, Tripani A, Mastrobarino S, Di Riso G, Castelpietra E, Risso FM. Parents experiencing NICU visit restrictions due to COVID-19 pandemic. Acta Paediatr 2021;110:940–1.
27. Bartlett AH, Ravan KA, Rubin LG, McGrath C, de St Maurice A, Linam WM, et al. SHEA Pediatric Leadership Council commentary: inpatient visitor considerations for pediatric patients during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 2021;42:1369–71.
28. Hwang SS, Weikel B, Adams J, Bourque SL, Cabrera J, Griffith N, et al. The Colorado Hospitals Substance-Exposed Newborn Quality Improvement Collaborative: standardization of care for opioid-exposed newborns shortens length of stay and reduces number of infants requiring opiate therapy. Hosp Pediatr 2020;10:783–91.
29. Achilles JS, Castaneda-Lovato J. A quality improvement initiative to improve the care of infants born exposed to opioids by implementing the Eat, Sleep, Console Assessment Tool. Hosp Pediatr 2019;9:624–31.
30. Blount T, Painter A, Freeman E, Grossman M, Sutton AG. Reduction in length of stay and morphine use for NAS with the “Eat, Sleep, Console” method. Hosp Pediatr 2019;9:615–23.
31. Dodds D, Koch K, Buitrago-Mogollon T, Horstmann S. Successful implementation of the Eat Sleep Console model of care for infants with NAS in a community hospital. Hosp Pediatr 2019;9:632–8.
32. Yang N, Che S, Zhang J, Wang X, Tang Y, Wang J, et al. Breastfeeding of infants born to mothers with COVID-19: a rapid review. Ann Transl Med 2020;8:818.
33. Han IL, Noble L. Covid-19 and breastfeeding: what’s the risk? J Perinatal 2020;40:1459–61.
34. Tomori C, Gribble K, Palmquist AEL, Ververs MT, Gross MS. When separation is not the answer: breastfeeding mothers and infants affected by COVID-19. Matern Child Nutr 2020;16:e13033.
35. Brown A, Shenker N. Experiences of breastfeeding during COVID-19: lessons for future practical and emotional support. Matern Child Nutr 2021;17:e13088.
36. Perrine CG, Chiang KV, Anstey EH, Grossniklaus DA, Boundy EO, Sauber-Schatz EK, et al. Implementation of hospital practices supportive of breastfeeding in the context of COVID-19—United States, July 15–August 20, 2020. MMWR Mortal Mortal Wkly Rep 2020;69:1767–70.
37. Pacheco F, Sobral M, Guimaraes R, de la Torre-Luque A, Caparros-Risso FM. Parents experiencing NICU visit restrictions due to virus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 2021;42:1369–71.
38. Snyder K, Worlton G. Social support during COVID-19: perspectives of breastfeeding practices, SARS-CoV-2 and its antibodies in the breast milk of mothers confirmed with COVID-19. Lancet Psychiatry 2020;4:100045.
39. Langabeer JR 2nd, Yatsco A, Champagne-Langabeer T. Telehealth sustains patient engagement in OUD treatment during COVID-19. J Subst Abuse Treat 2021;122:108215.